Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Thomas R Malek"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Development of interleukin (IL)-2-dependent antitumor responses focus on targeting the intermediate affinity IL-2R to stimulate memory-phenotypic CD8+ T and natural killer (NK) cells while minimizing regulatory T cell (Treg) expansion. How
Externí odkaz:
https://doaj.org/article/80abefd9db3649d192d0243c632b987d
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/49472d5967644776960427a0c7300573
Autor:
Rosmely Hernandez, Thomas R. Malek
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Cancer vaccines offer the potential to enhance T cell-mediated antitumor immunity by expanding and increasing the function of tumor-specific T cells and shaping the recall response against recurring tumors. While the use of cancer vaccines is not a n
Externí odkaz:
https://doaj.org/article/0c56696c3e284618a5bb4c4568ae7836
Publikováno v:
Diabetes. 72:769-780
Low-dose IL-2 is a promising immunotherapy in clinical trials for treating type 1 diabetes. A new IL-2 analog, IL-2/CD25 fusion protein, has been shown to more efficiently delay or prevent diabetes in NOD mice by expanding the population of activated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86f8204c3c60e07ee261def225450c77
https://doi.org/10.2337/db22-0482
https://doi.org/10.2337/db22-0482
Publikováno v:
Nature Reviews Immunology. 22:614-628
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f31dc5b0918e7b6587a84f1b7c09d423
https://doi.org/10.1038/s41577-022-00680-w
https://doi.org/10.1038/s41577-022-00680-w
Low-dose IL-2 is a promising immunotherapy in clinical trials for treating type 1 diabetes. A new IL-2 analog, IL-2/CD25 fusion protein, has been shown to more efficiently delay or prevent diabetes in NOD mice by expanding the population of activated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16967a72285fc29f4e2994c235ff71bd
https://doi.org/10.2337/figshare.22280644
https://doi.org/10.2337/figshare.22280644
Autor:
Henry Barreras, Sabrina N. Copsel, Cameron S. Bader, Ying Ding, Dietlinde Wolf, Charles Cash, Caleb J. Stacey, Cara Benjamin, Mathew M. Seavey, Jeffrey Wolf, Rahul R. Jasuja, Brent Pfeiffer, Geoffrey R. Hill, Krishna V. Komanduri, Roland Jurecic, Thomas R. Malek, Robert B. Levy
Publikováno v:
Transplantation and Cellular Therapy. 29:341.e1-341.e9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f082fbc00f2201c06f5a4d6664319b4
https://doi.org/10.1016/j.jtct.2023.02.015
https://doi.org/10.1016/j.jtct.2023.02.015
Publikováno v:
Am J Pathol
Regulatory T cells (Tregs) are non-redundant mediators of immune tolerance that are critical to prevent autoimmune disease and promote an anti-inflammatory tissue environment. Many individuals experience chronic diseases and physiologic changes assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01db3dbeabe4dbf3c26945a942ce3ad4
https://doi.org/10.1016/j.ajpath.2020.07.012
https://doi.org/10.1016/j.ajpath.2020.07.012
Autor:
Thomas R. Malek, Alicia Santos Savio, Connor J. Dwyer, Jenny Xie, Aixin Yu, Rosmely Hernandez, Mary Struthers, Liping Yu, Jen Bon Lui, Natasha C. Ward, Sunnie Hsiung
Publikováno v:
Diabetes
Low-dose interleukin-2 (IL-2) represents a new therapeutic approach to regulate immune homeostasis to promote immune tolerance in patients with autoimmune diseases, including type 1 diabetes. We have developed a new IL-2–based biologic, an IL-2/CD2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15bfdfe95b7de2b2a96cf36840be32d4
https://doi.org/10.2337/db20-0186
https://doi.org/10.2337/db20-0186
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundImmunization with tumor neoantigens is a promising vaccine approach to promote antitumor immunity due to their high immunogenicity, lack of expression in normal tissue, and preferential induction of tumor neoantigen-specific T cells, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10ceed3c45a8a93e62fbdfb10ac8ab34
https://jitc.bmj.com/content/9/9/e002865.full
https://jitc.bmj.com/content/9/9/e002865.full